Company profile: Remynd
1.1 - Company Overview
Company description
- Provider of investigational programs for CNS protein misfolding disorders, including ReS19-T for Alzheimer’s, ReS18-H for Huntington’s, and ReS3-T for Alzheimer’s and epilepsy, plus a CRO that assesses pharmacokinetics, pharmacodynamics, and efficacy in proprietary animal models, and a phenotypic screening platform to discover small-molecule treatments and novel targets.
Products and services
- Contract Research Organization (CRO): In-vivo service that assesses pharmacokinetics, pharmacodynamics, and efficacy of experimental CNS treatments in proprietary mouse models, delivering pivotal proof-of-concept data to Top-10 pharmas
- Discovery Platform: Proprietary phenotypic screening system that discovers small-molecule treatments for protein misfolding disorders, identifying novel targets and mechanisms of action
- ReS19-T: Investigational compound for Alzheimer's engineered to restore synaptic plasticity and reduce amyloid plaques and tau tangles, targeting disease modification
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Remynd
DCN Diagnostics
HQ: United States
Website
- Description: Provider of lateral flow diagnostics development and manufacturing services, offering contract assay development across lateral flow, flow-through, dry chemistry, and microfluidic formats; design and integration of custom point-of-use readers and lab-on-a-chip systems; scalable manufacturing from clinical trials to commercialization; user-friendly sample collection devices and cartridges; and visual/fluorescent labeling and reporting solutions.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full DCN Diagnostics company profile →
Lipofabrik
HQ: France
Website
- Description: Provider of biological and biodegradable molecules produced through bioprocesses based on renewable resources, including lipopeptides such as Fengycin, Plipastatin, Iturin, Lichenysin, Mycosubtilin, and Surfactin.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Lipofabrik company profile →
Biosynthetic Technologies
HQ: United States
Website
- Description: Provider of biobased synthetic molecules and oils made from organic fatty acids found in plant oils for lubricant, chemical, and cosmetics applications. Products include Estolides and BioEstolides, sustainable industrial lubricant base oils, metalworking fluid additives, hydraulic oils, and personal care ingredients offering stability, lubricity, wear protection, and biodegradability.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Biosynthetic Technologies company profile →
Double Rainbow Biosciences
HQ: United States
Website
- Description: Provider of sustainable supply of active pharmaceutical ingredients; access to rare or endangered ingredients for consumer health products; bioengineering solutions for ag tech addressing global food insecurity; PRISM enzyme modification platform to improve specificity and efficacy of medicines via glycosylation; HARMONY molecular biosynthesis platform for sustainable recreation of bioactive compounds; and biosynthetic production of Gastrodin.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Double Rainbow Biosciences company profile →
Xceleron
HQ: United States
Website
- Description: Provider of Accelerator Mass Spectrometry (AMS) services delivering ultra-sensitive analytical solutions for drug development.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Xceleron company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Remynd
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Remynd
2.2 - Growth funds investing in similar companies to Remynd
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Remynd
4.2 - Public trading comparable groups for Remynd
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →